These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34407702)

  • 1. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis.
    Rizzo A; Merler S; Sorgentoni G; Oderda M; Mollica V; Gadaleta-Caldarola G; Santoni M; Massari F
    Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1237-1243. PubMed ID: 34407702
    [No Abstract]   [Full Text] [Related]  

  • 2. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
    Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
    Zhang X; Zhang G; Wang J; Bi J
    Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes.
    Di Nunno V; Mollica V; Santoni M; Gatto L; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2019 Oct; 17(5):e871-e877. PubMed ID: 31378578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
    Appukkuttan S; Ko G; Fu C; Bannister B; Kong SX; Jhaveri J; Freedland SJ
    Expert Rev Anticancer Ther; 2024 May; 24(5):325-333. PubMed ID: 38469875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
    Rizzo A; Oderda M; Mollica V; Merler S; Morelli F; Fragomeno B; Taveri E; Sorgentoni G; Santoni M; Massari F
    Anticancer Drugs; 2022 Jan; 33(1):e43-e51. PubMed ID: 34387593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
    BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
    El-Taji O; Taktak S; Jones C; Brown M; Clarke N; Sachdeva A
    JAMA Oncol; 2024 Jul; 10(7):874-884. PubMed ID: 38842801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
    Liu Z; Zhang T; Ma Z; Zheng S; Chen J; Wu Z; Zheng X; Li X; Liu Z
    Am J Clin Oncol; 2020 Apr; 43(4):288-297. PubMed ID: 31972568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; De Cobelli O; Nolè F
    Eur J Cancer; 2015 Sep; 51(14):1970-7. PubMed ID: 26169016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
    Morgans AK; Shore N; Cope D; McNatty A; Moslehi J; Gomella L; Sartor O
    Urol Oncol; 2021 Jan; 39(1):52-62. PubMed ID: 32958445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide.
    Fujmoto S; Fujita K; Nishimoto M; Hamaguchi M; Kuwahara K; Hashimoto M; Adomi S; Minami T; Nozawa M; Yoshimura K; Uemura H
    Cancer Med; 2023 Feb; 12(3):3176-3179. PubMed ID: 36043427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
    Cao B; Kim M; Reizine NM; Moreira DM
    Eur Urol Oncol; 2023 Jun; 6(3):237-250. PubMed ID: 36682938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.